Repros Therapeutics, Inc. (RPRX) Reports Q2 Loss of $0.30
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $58.60 +0.07%
Financial Fact:
General and administrative: 997K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
General and administrative: 997K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.30), versus ($0.20) reported last year. Revenue for the quarter came in at $1 thousand, versus $53 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
